Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Skin Neoplasms × spartalizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Pancreatic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Triple Negative Breast Neoplasms 4 Head and Neck Neoplasms 3 Sarcoma 2 Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Liver Neoplasms 2 Carcinoma, Renal Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinocerebellar Degenerations 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Kidney Neoplasms 1 Kidney Diseases 1

Interventions

aldesleukin 14 Cyclophosphamide 14 fludarabine phosphate 11 fludarabine 11 Interleukin-2 9 Ipilimumab 6 Temozolomide 4 Nivolumab 4 trametinib 2 sonidegib 2 pembrolizumab 2 dabrafenib 2 binimetinib 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Sodium Chloride 2 Sirolimus 2 Radiotherapy 2 Radiation 2 Peptides 2 Gefitinib 2 Fluorouracil 2 Dacarbazine 2 Cyclosporine 2 Capecitabine 2 veliparib 1 varlilumab 1 tilsotolimod 1 spartalizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02967692 2025-09-18

COMBI-i

Novartis

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡